;

The Babraham Investor Conference, Wednesday 9th June 2021, 2 – 3.30pm

The Babraham Investor Conference 2021 (BIC) is a virtual event for investors focusing on early-stage and scale-up life science and med-tech companies.  

The event features a programme of start-up and scale-up company presentations, with keynote presentations from Daniel Mahony, co-head of healthcare, Polar Capital and Martin Murphy, CEO, Syncona.

The Babraham Investor Conference is open to Investors only; if you would like to attend, please email register@babraham.co.uk stating your name, company details and web address.

VIRUTAL EVENT
FOR 2021

PITCHES FROM START-UP
& SCALE-UP COMPANIES

EARLY-STAGE SCIENCE
& MED-TECH COMPANIES

SPEAKERS FROM LIFE-SCIENCE
COMPANIES & INVESTORS

BIC 2021 Programme

Our programme will feature a rich array of company presentations and digital networking opportunities. During the course of the day you can expect:

  • Company presentations.
  • Pitches from both start-up and scale up companies seeking investment.
  • Multiple opportunities to network with contacts and make new connections.

Speakers

Martin Murphy

Martin Murphy is CEO of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside the Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He was previously Chairman of Blue Earth Diagnostics, which Syncona sold to Bracco Imaging for $476 million in 2019. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.

Daniel Mahony

Daniel Mahony is Co-Head of the Healthcare team at  Polar Capital. He studied biochemistry at the University of Oxford and  received his Ph.D. from the University of Cambridge. Daniel moved to  California to work as a research scientist at Schering Plough  Corporation (now Merck & Co.) in 1995 and made the transition into  financial services in 1998, working for ING Barings in New York and  Morgan Stanley in London as head of the European healthcare research  team. In 2007, he set up Polar Capital’s healthcare team. He has over 29  years of experience within global healthcare covering sectors including  biotechnology, medical technology and healthcare services.

Sponsors

Handelsbanken

Handelsbanken is a full-service bank with a decentralised way of working, a strong local presence due to a nationwide network of over 200 branches and a long-term approach to customer relations.

Explore More

Taylor Vinters

Taylor Vinters is an international law firm supporting the businesses which drive the innovation economy, and the entrepreneurs and private wealth that underpin them.

Explore More

Contact us

BABRAHAM RESEARCH
CAMPUS

(+44) 1223 496 000
info@babraham.co.uk

Babraham Bioscience Technologies Ltd
Babraham Research Campus
Cambridge
CB22 3AT, United Kingdom

Press Enquiries

Limewash
01223 813 557
info@limewash.co.uk

Subscribe to our mailing list

Please enter your first name
Please enter your surname
Please enter your email address
Submit
; ;